|Videos|October 5, 2017

What Makes Eravacycline a Unique Antibiotic?

Author(s)Contagion&reg Editorial Staff

Patrick Horn, MD, PhD, explains why eravacycline is a unique antibiotic and how it stands up against many different types of pathogens, including those that are multidrug-resistant.

Patrick Horn, MD, PhD, chief medical officer at Tetraphase Pharmaceuticals explains why eravacycline is a unique antibiotic and how it stands up against many different types of pathogens, including those that are multidrug-resistant.

Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.

Subscribe Now!

What Makes Eravacycline a Unique Antibiotic?

Newsletter

Related Content

Nearly 1 in 5 Urinary Tract Infections in Southern California Linked to Contaminated Meat

High Continued Adherence of Lenacapavir in Individuals Who Use Substances and Alcohol

Meet SIDP’s President Elect: Lisa Dumkow, PharmD, FIDP, BCIDP

Dynavax Presents Data for Shingles Vaccine, Launches Head-to-Head Study Against Shingrix

Introducing Cefiderocol Earlier in Difficult-to-Treat-Infections

Latest CME

Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice

Community Practice Connections™: Navigating Early-Stage HR+/HER2‒- Breast Cancer – Clinical Developments and Innovative Treatments

Expert Illustrations and Commentaries™: The Role of the Paracellular Pathway in the Management of Hyperphosphatemia in CKD

Advances In: Managing Hyperphosphatemia in Chronic Kidney Disease – Bridging Treatment Gaps With Novel Therapies

Addressing Pivotal Updates in AML – Expert Perspectives on Individualizing Management for Special Populations

Burst CME™ Part 3: Initiating Early Intervention in Patients With Glaucoma Who Fail Pharmacological Therapy

Advances In™: Taking R/R B-Cell ALL Management to the Next Level With New CAR T Approval

Innovations in MDS Care: Navigating New Treatment Paradigms, Breakthrough Therapies, and Emerging Clinical Evidence

Cases & Conversations™: Integrating Novel Approaches to Treatment in First-line ALK+ mNSCLC – Enhancing Patient Outcomes with Real World Multidisciplinary Strategies

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Interventional Glaucoma Treatment: Evolving Paradigms for Addressing Unmet Needs

Cases and Conversations™: Navigating the Complexities of Managing Myasthenia Gravis in Pediatric and Pregnant Patient Populations

Identifying and Treating CIDP in the Modern Era

Cases and Conversations™: Little Voices, Big Challenges – Comprehensive Care for Pediatric Spinal Muscular Atrophy

Burst CME™: Addressing Inadequate Response to Anti-TNF Therapy in Patients With Rheumatoid Arthritis

Breast Cancer Symposia in San Antonio

Dermalorian™ Webinar: Shedding Light on Patient-Reported Outcomes to Assess Disease Severity in Patients With Atopic Dermatitis

Community Practice Connections™: Cases and Conversations – Keeping Up with Novel Approaches to Managing ANCA-Associated Vasculitis

(COPE Credit) Community Practice Connections™: Applying Advances in Neovascular Retinal Disease - Expanding Treatment Intervals & Enhancing Outcomes

Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care

(CME Track) Neurotrophic Keratitis in Focus – From Early Recognition to Strategic Intervention

(COPE Track) Neurotrophic Keratitis in Focus – From Early Recognition to Strategic Intervention

Addressing Racial Disparities in Multiple Myeloma: Forging a Path Towards Health Equity in Clinical Trials and Everyday Practice

(CME Track) Leveraging Rho Kinase Inhibition in Glaucoma Management — How Can Novel Treatment Pathways Impact Patient Outcomes?

Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?

Evolving Strategies and Emerging Agents in PTCL: Subtypes, Mutations, and Modern Therapies

Rounds with Dr Jabbour: Breaking Barriers in ALL Treatment

Community Practice Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2- Breast Cancer

Burst CME™: Exploring Diagnosis and Testing Innovations for Targetable Mutations in SCLC

Burst CME™: Addressing Diagnostic Challenges and Identifying Targets for Treatment in LCNEC-L

Community Practice Connections™: 21st Annual Meeting of the International Society of Gastrointestinal Oncology

Medical Crossfire®: Optimal Approaches to Evaluating and Addressing Pain in the Patient With Sickle Cell Disease

Burst CME™: Advanced Diagnostic and Testing Approaches for Mutation-Targetable Management of NSCLC

Community Practice Connections™: Case Discussions in TNBC… Navigating the Latest Advances and Impact of Disparities in Care

Addressing Health Care Inequities™: Taking a More Mindful Approach to the Care of Every Patient Presenting With ATTR-CM

Clinical Case Vignette Series™: 3rd Annual International Congress on Pediatric Oncology

Collaborating Across the Continuum®: Identifying and Treating Epithelioid Sarcoma

Medical Crossfire®: Improving Survival in HR-Positive HER2-Negative Metastatic Breast Cancer – Advances in Selective Estrogen Receptor Targeting Therapies

Medical Crossfire®: Bridging Expert Guidance and Evidence-Based Recommendations in the Ever-Evolving Treatment of MF, PV, and ET

From Barriers to Breakthroughs in Multiple Myeloma: How Trials Compare to the Real-World Management of Patients in Your Practice

Show Me the Data: How Do We Navigate the Latest Evidence on Novel Therapies and Trials Across GvHD Prophylaxis, Acute, and Chronic Care?

Show Me the Data™: Pushing CAR Ts Forward Across Lymphoid Malignancies…Accelerating Access in the Community and the Treatment Strategies for the Road Ahead

Medical Crossfire®: New Horizons in Acute Lymphoblastic Leukemia—How The Experts Apply New Evidence from AYA to Adult Scenarios

Real Psychiatry 2026

19th Annual New York GU Cancers Congress™

Upstate New York Hematology & Hematologic Oncology Conference: A Review of the 67th ASH Annual Meeting

43rd Annual Miami Breast Cancer Conference®

17th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies™

Mind Moments™: Optimizing Management for Patients with Generalized Myasthenia Gravis

Transforming Treatment in Small Cell Lung Cancer: How Recent Trials Are Shaping Treatment Decision-Making and Future Therapies

Burst CME™: Stratifying Therapy Sequencing for LGSOC and Evaluating the Unmet Needs of the Standard of Care

(CME Track) Burst CME™ Part 1: Insights Into Glaucoma and the Need for Early Intervention

Homing in on the Role of PSMA in Prostate Cancer – Harnessing the Power of Precision Medicine Through Imaging and Therapy to Individualize Treatment Plans

2nd Annual Hawaii Cancer Conference

Patient, Provider & Caregiver Connection™: Understanding the Patient Journey to Provide Personalized Care for Generalized Pustular Psoriasis

Medical Crossfire®: Integrating Real-World Data to Improve Outcomes for Patients With Multiple Sclerosis

Medical Crossfire® - Optimizing Management for Patients With Generalized Myasthenia Gravis: Focus on Complement Inhibitors

Collaborating Across the Continuum™: Identifying and Preventing Hepatic Encephalopathy in Long-Term Care Settings

Community Practice Connections™: Transforming Treatment in nAMD, DME, and DR – Keeping an Eye on Optimal Outcomes

Raising Our Game in the Management of Hyperlipidemia: New Targets, New Tactics

Medical Crossfire®: New Horizons in Hemolytic Anemias – How I Diagnose & Treat Based on Individual Patient and Disease Characteristics

(MOC and CME Credit) New Frontiers in Immunotherapy for SCLC: Insights From Latest Clinical Trials and Their Application in Real-World Treatment

Evolving Perspectives in Alzheimer Disease : Reaching an Earlier Diagnosis, Understanding Neuroinflammation, and Exploring Therapeutic Advances

(CME Credit Only) New Frontiers in Immunotherapy for SCLC: Insights From Latest Clinical Trials and Their Application in Real-World Treatment

Community Practice Connections™: Optimizing the Management of Tardive Dyskinesia—Addressing the Complexity of Care With Targeted Treatment

(CME) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care

(MOC and CME Credit) Lung Cancer Tumor Board®: The Pivotal Role of Multimodal Therapy in Leveraging Immunotherapy for Stage I-III NSCLC When the Goal Is Cure

(CME Credit Only) Lung Cancer Tumor Board®: The Pivotal Role of Multimodal Therapy in Leveraging Immunotherapy for Stage I-III NSCLC When the Goal Is Cure

Burst CME™: Setting the Stage – Individualizing Migraine Care for Diverse Populations Across Care Settings

Expert Illustrations & Commentaries™: Visualizing the Role of B Cells as Therapeutic Targets for Generalized Myasthenia Gravis

Annual Hematology Meeting: Preceding the 67th ASH Annual Meeting and Exposition